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Tau aggregation occurs in neurodegenerative dis-
eases including Alzheimer’s disease and many other
disorders collectively termed tauopathies. trans-
cellular propagation of tau pathology, mediated by
extracellular tau aggregates, may underlie pathogen-
esis of these conditions. P301S tau transgenic mice
express mutant human tau protein and develop pro-
gressive tau pathology. Using a cell-based biosensor
assay, we screened anti-tau monoclonal antibodies
for their ability to block seeding activity present in
P301S brain lysates. We infused three effective anti-
bodies or controls into the lateral ventricle of P301S
mice for 3 months. The antibodies markedly reduced
hyperphosphorylated, aggregated, and insoluble tau.
They also blocked development of tau seeding activ-
ity detected in brain lysates using the biosensor
assay, reduced microglial activation, and improved
cognitive deficits. These data imply a central role for
extracellular tauaggregates in thedevelopmentofpa-
thology. They also suggest that immunotherapy spe-
cifically designed to block trans-cellular aggregate
propagation will be a productive treatment strategy.
INTRODUCTION
Tau is a microtubule-associated protein that forms intracellular
aggregates in several neurodegenerative diseases collectively
termed tauopathies. These include Alzheimer’s disease (AD),
progressive supranculear palsy (PSP), corticobasal degenera-
tion (CBD), and frontotemporal dementia (FTD) (Mandelkow
and Mandelkow, 2012). Tau is a highly soluble and natively
unfolded protein (Jeganathan et al., 2008) that binds and
promotes the assembly of microtubules (Drechsel et al., 1992;
Witman et al., 1976). In tauopathies, tau accumulates in hyper-
phosphorylated neurofibrillary tangles (NFTs) that are visualized402 Neuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc.within dystrophic neurites and cell bodies (Mandelkow andMan-
delkow, 2012). The amount of tau pathology correlates with pro-
gressive neuronal dysfunction, synaptic loss, and functional
decline in humans and transgenic mouse models (Arriagada
et al., 1992; Bancher et al., 1993; Polydoro et al., 2009; Small
and Duff, 2008).
In human tauopathies, pathology progresses from one brain
region to another in disease-specific patterns (Braak and Braak,
1997; Raj et al., 2012; Seeley et al., 2009; Zhou et al., 2012),
although the underlying mechanism is not yet clear. The prion
hypothesis holds that tau aggregates escape cells of origin to
enter adjacent cells, where they seed further tau aggregation
and propagate pathology (Frost and Diamond, 2010). We have
previously observed that recombinant tau fibrils will induce
aggregation of full-length intracellular tau in cultured cells and
that aggregated forms of tau transfer between cells (Frost
et al., 2009). Further, we found that intracellular tau fibrils are
released free into the media, where they propagate aggregation
by direct interaction with native tau in recipient cells. An anti-tau
antibody (HJ9.3) blocks this process by preventing tau aggre-
gate uptake into recipient cells (Kfoury et al., 2012). In addition
to similar experiments with recombinant tau (Guo and Lee,
2011), others have shown that paired helical filaments from AD
brain induce cytoplasmic tau aggregation (Santa-Maria et al.,
2012). Injection of brain extract from human P301S tau trans-
genic mice into the brains of mice expressing wild-type human
tau induces assembly of wild-type human tau into filaments
and spreading of pathology (Clavaguera et al., 2009). Similar
effects occurred after injection of recombinant full-length or trun-
cated tau fibrils, which caused rapid induction of NFT-like inclu-
sions that propagated from injected sites to connected brain
regions in a time-dependent manner (Iba et al., 2013). Selective
tau expression in the entorhinal cortex caused late pathology in
the axonal terminal zones in cells in the dentate gyrus and hippo-
campus, consistent with transsynaptic movement of aggregates
(de Calignon et al., 2012; Liu et al., 2012). A growing body of work
thus supports the idea that tau aggregates transfer between cells
and might be targeted with therapeutic antibodies.
In mouse models that mimic aspects of AD and Parkinson’s
disease, passive immunization using antibodies against Ab and
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brain (Bard et al., 2000; DeMattos et al., 2001; Masliah et al.,
2011) and improve behavioral deficits (Dodart et al., 2002; Koti-
linek et al., 2002; Masliah et al., 2011). Active immunization in
tauopathy mouse models using tau phospho peptides reduced
tau pathology (Bi et al., 2011; Boimel et al., 2010) and in some
studies improved behavioral deficits (Asuni et al., 2007; Bouta-
jangout et al., 2010; Troquier et al., 2012). In two passive vacci-
nation studies, there was reduced tau pathology and improved
motor function when the antibody was given prior to the onset
of pathology (Boutajangout et al., 2011; Chai et al., 2011). While
several of the tau immunization studies appear to show some
beneficial effects, the maximal expected efficacy of anti-tau
antibodies administered after the onset of pathology, the optimal
tau species to target, and the mechanism of the therapeutic
effect have remained unknown.
Our prior work in cell culture has suggested that aggregate flux
in and out of cells might be central to progressive pathology
(Kfoury et al., 2012). Thus, we predicted that antibodies that spe-
cifically block P301S brain-derived seeding activity might block
propagation between cells and decrease overall tau pathology.
We have used P301S human tau transgenic mice (Yoshiyama
et al., 2007) to test intracerebroventricular (ICV) administration
of three different anti-tau antibodies selected for their ability to
block tau seeding activity in vitro and to block tau uptake into
cells.
RESULTS
Characterization of Anti-Tau Antibodies
Wehave previously observed that tau aggregates, but notmono-
mer, are up taken by cultured cells and that internalized tau
aggregates trigger intracellular tau aggregation in recipient cells
(Frost et al., 2009; Kfoury et al., 2012). We characterized the HJ8
series of eight mouse monoclonal antibodies (raised against full-
length human tau) and HJ9 series of five antibodies (raised
against full-length mouse tau) in an adapted cellular biosensor
system we have previously described (Kfoury et al., 2012) that
measures cellular tau aggregation induced by the addition of
brain lysates containing tau aggregates. The antibodies had
variable effects in blocking seeding, despite the fact that all an-
tibodies efficiently bind tau monomer and stain neurofibrillary
tangles. We selected three antibodies with different potencies
in blocking seeding for our studies.
Prior to testing in vivo, we determined the binding affinities and
epitopes of the antibodies, which are all IgG2b isotype. We
immobilized human andmouse tau on a sensor chip CM5 for sur-
face plasmon resonance (SPR) (Figure 1). The HJ9.3 antibody,
raised against mouse tau, recognizes both human (Figure 1A)
and mouse (Figure 1B) tau with the same binding constant
(KD = Kd/Ka = 100 pM) (Figure 1G). The association (Ka) and
dissociation (Kd) rate constants were calculated by using
BIAevaluation software (Biacore AB) selecting Fit kinetics simul-
taneous Ka/Kd (Global fitting) with 1:1 (Langmuir) interaction
model. The Ka and Kd of HJ9.3 toward human (Ka = 7.5 3
104 Ms1, Kd = 7.5 3 10
6 s1) and mouse (Ka = 8.6 3
104 Ms1, Kd = 9.1 3 10
6 s1) indicate strong binding to both.
We mapped the epitope of HJ9.3 to the repeat domain (RD) re-gion, between amino acids 306–320. HJ9.4, raised against
mouse tau, had high affinity KD (2.2 pM) toward mouse tau
with a high association rate constant (Ka = 2.28 3 10
5 Ms1)
and very low dissociation constant (Kd = 5.13 10
7 s1) (Figures
1D and 1G). However, the same antibody had a much lower
affinity (KD = 6.9 nM) toward human tau (Figures 1C and 1G),
with a similar association rate constant (Ka = 1.5 3 10
5 Ms1)
as mouse tau but with much faster dissociation (Kd = 1.07 3
103 s1). Thus, the HJ9.4 interaction with human tau is less sta-
ble than with mouse tau. The epitope for this antibody is amino
acids 7–13. HJ8.5 was raised against human tau. It binds to hu-
man tau (Figure 1E) but not to mouse tau (Figure 1F). The KD
(0.3 pM) (Figures 1E and 1G) and low dissociation rate (Kd =
4.38 3 108 s1) indicate that HJ8.5 binds human tau with very
high affinity. We mapped the epitope of HJ8.5 to amino acids
25–30. All three anti-tau antibodies strongly recognized human
tau fibrils on SPR (Figure S1 available online). Because the fibrils
have multiple identical epitopes, we could not directly calculate
the association and dissociation rates.
We also assessed the antibodies by immunoblotting and
immunostaining. On western blots, all three antibodies bound
to human tau (Figure 1H). HJ9.3 and HJ9.4 bound to mouse
tau, while HJ8.5 did not (Figure 1H). Consistent with our prior
findings (Yamada et al., 2011), there appeared to be less reas-
sembly buffer (RAB)-soluble tau in 9-month-old compared to
3-month-old P301S mice. We found that HJ8.5 stained human
tau in 3-month-old and 9- to 12-month-old transgenic P301S
mouse brains. Tau immunoreactivity was present throughout
the cell bodies and processes (Figure S2). In 9- to 12-month-
old P301S mice with tau aggregates, HJ8.5 detected tau aggre-
gates in cell bodies (Figure S2A). Other antibodies produced
similar results (Figure S2B). All antibodies bound to neurofibril-
lary tangles and neuropil threads in AD brain (Figure S2).
Tau Antibodies Block the Uptake and Seeding Activity
of P301S Tau Aggregates
To evaluate seeding activity present in P301S brain lysates, we
adapted a cellular biosensor system that we have previously
described (Kfoury et al., 2012). This is based on expression of
the repeat domain of tau (aa 243–375) containing the DK280
mutation fused either to cyan or yellow fluorescent protein
(RD(DK)-CFP/YFP). Uptake of exogenous aggregates into these
cells triggers intracellular aggregation of RD(DK)-CFP/YFP that is
detected by fluorescence resonance energy transfer (FRET)
recorded on a fluorescence plate reader (Kfoury et al., 2012).
Clarified brain lysates from 12-month-old P301S mice added
to the biosensor cell system induced strong aggregation of the
RD(DK)-CFP/YFP reporter, indicating the presence of tau seed-
ing activity (Figure 2A). The seeding activity from 12-month-old
P301S brain homogenate mice roughly corresponds to 50 nM
(monomer equivalent) of recombinant full-length fibrils (data
not shown).
There was little to no aggregation induced by lysates from tau
knockout mice, wild-type mice, or 3-month-old P301S mice
lacking tau pathology (Figure 2A). We assessed the anti-tau
antibodies (HJ8.5, HJ9.3, and HJ9.4) for their ability to block
the uptake and seeding activity from the 12-month-old P301S
brain lysates. HJ3.4 (mouse monoclonal anti-Ab antibody) wasNeuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc. 403
Figure 1. Characterization of Anti-Tau Antibodies by Surface Plasmon Resonance and Immunoblotting
Surface plasmon resonance (SPR) sensorgrams showing the binding of each anti-tau antibody toward immobilized recombinant human tau (longest isoforms
hTau40, 441 aa) and immobilized mouse tau (longest isoforms mTau40, 432 aa). Each antibody was run with various concentrations (0.11, 0.23, 0.46, 0.90, 1.8,
3.7, and 7.5 mg/ml) and plots are shown in the corresponding color.
(A and B) SPR sensorgrams of HJ9.3 antibody binding to immobilized human tau (A) and immobilized mouse tau (B).
(C and D) SPR sensorgrams of HJ9.4 antibody binding to immobilized human tau (C) and immobilized mouse tau (D).
(E and F) SPR sensorgrams of HJ8.5 antibody binding to immobilized human tau (E) and mouse tau (F).
(G) Table showing the association rate constant (Ka), dissociation rate constant (Kd), and binding constant (KD) of each antibody toward human and mouse tau.
BIAevaluation software (Biacore AB) was used to calculate Ka and Kd by selecting Fit kinetics simultaneous Ka/Kd (Global fitting) with 1:1 (Langmuir) interaction
model. Ms1, millisecond; M, molar; s, second.
(H) RAB-soluble fractions of 3-month-old tau knockout (KO), 3-month-old wild-type (WT), 3-month-old P301S (3mo), and 9-month-old P301S (9mo) mice were
analyzed by immunoblot by using the indicated anti-tau antibodies.
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seeding activity (Figure 2B). To determine their relative efficacy,
we titrated the antibodies (0.125, 0.25, 0.5, 1, and 2 mg/ml)
against a fixed amount of P301S brain lysate (Figure 2C). The
HJ8.5 antibody blocked seeding activity at concentrations as
low as 0.25 mg/ml compared to controls. At 0.5 mg/ml, both
HJ8.5 and HJ9.3 antibody significantly blocked uptake and
seeding activity compared to control. HJ9.4 was least potent in
blocking the uptake and seeding activity, consistent with its
higher affinity for mouse tau. All three anti-tau antibodies de-
tected tau aggregates internalized after uptake by HEK293 cells,
as detected by post hoc cellular permeabilization and staining.
However, when these antibodies were preincubated with and404 Neuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc.without P301S brain lysates, none of these antibodies were
detected inside cells upon staining with anti-mouse secondary
antibody (Figure S3). While other modes of inhibition are
possible, these data are consistent with a mechanism based
on blocking cellular uptake of tau aggregates.
To further assess tau seeding activity present in TBS-soluble
P301S brain lysates, we immunoprecipitated lysates with the
different antibodies and assessed both the bound and unbound
fractions for seeding activity. After control HJ3.4 immunoprecip-
itation, the unbound fraction had strong seeding activity and the
immunoprecipitatedmaterial had no seeding activity (Figure 2D).
After immunoprecipitaton with HJ8.5 and HJ9.3, the unbound
fraction had no significant seeding activity, and with HJ9.4, the
Figure 2. Tau Antibodies Block the Uptake
and Seeding Activity of P301S Tau Aggre-
gates as Detected by a FRET Assay
(A) HEK293 cells expressing RD (DK280)-CFP/YFP
were exposed to 2.5 mg of total protein of 13 TBS
brain lysates for 24 hr. Brain lysates collected from
12-month-old P301S mice induced much greater
seeding activity (n = 5) as compared to lysates from
knockout (KO) mice (n = 7), wild-type (WT) mice
(n = 6), or young 3-month-old P301S mice (n = 2).
****p < 0.0001 versus other groups.
(B) HEK293 cells were cotransfected with RD
(DK280)-CFP and RD (DK280)-YFP. Eighteen
hours later, preincubated P301S brain lysates with
or without incubation of anti-tau antibodies (HJ8.5,
HJ9.3, and HJ9.4) or control antibody (HJ3.4, anti
Ab antibody) were added to cells. We found all the
tau antibodies incubated with P301S brain lysates
significantly blocked seeding activity. Statistical
significance was determined by one-way ANOVA
followed by Dunnett’s post hoc test for multiple
comparisons by using GraphPad Prism 5.0 soft-
ware. ***p > 0.001.
(C) Titration of these antibodies with various con-
centrations (0.125 mg/ml, 0.25 mg/ml, 0.5 mg/ml,
1 mg/ml, and 2 mg/ml) was performed with a fixed
amount of P301S brain lysates. Twenty-four hours
later, FRET analysis was performed. Out of all tau
antibodies we used, HJ8.5 was the most potent in
blocking the uptake and seeding activity of P301S
brain lysates. Statistical significance was deter-
mined by two-way ANOVA followed by Bonferroni
post hoc test for multiple comparisons. **p <
0.0001, *p < 0.01. Values represent mean ± SEM.
(D–F) Immunoprecipitated (IP) and depleted su-
pernatant (Sup) of P301S brain lysate of all anti-tau
antibodies (HJ8.5, HJ9.3, and HJ9.4) and control
antibody (HJ3.4) were analyzed by tau seeding assay (D), SDD-AGE followed bywestern blot (E), and SDS-PAGE followed bywestern blot (F). Monomeric (M) and
fibrillized (F) recombinant human tau (rTau) was used as controls for SDD-AGE and monomeric rTau was used for SDS-PAGE as a control. hTau indicates human
tau and mTau indicates endogenous mouse tau.
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from the anti-tau antibodies, the immunoprecipitated material
had strong seeding activity. To assess the tau seeds, we
analyzed these fractions by nondenaturing blots (semidena-
turing detergent-agarose gel electrophoresis [SDD-AGE]) (Half-
mann and Lindquist, 2008) and by denaturing blots (SDS-PAGE)
followed by western blotting for tau. SDD-AGE of immunopre-
cipitated tau revealed monomer and multiple larger species
that are probably oligomeric (Figure 2E). The unbound material
had some residual tau species but less than what was present
in the immunoprecipated material. HJ3.4 did not immunoprecip-
itate any tau species. Western blot following SDS-PAGE (Fig-
ure 2F) revealed that the tau multimers were denatured to pre-
dominantly tau monomer, but the overall patterns were similar.
Although tauopathy is associated with detergent-insoluble tau,
we observed that TBS-soluble brain lysates contain tau seeding
activity. To characterize the tau present in this fraction, we eval-
uated the immunoprecipitated material by atomic force micro-
scopy (AFM). HJ3.4 immunoprecipiated no aggregated material.
Interestingly, each tau antibody immunoprecipitated unique
forms of aggregated material (Figure 3), consistent with a multi-
plicity of aggregated tau species.Intracerebroventricular Infusion of Anti-Tau Antibodies
In our colonies, P301S mice first develop intracellular tau pathol-
ogy beginning at 5months of age. To test the efficacy of the three
antibodies by chronic intracerebroventricular (ICV) administra-
tion, we surgically implanted a catheter into the left lateral
ventricle of each mouse at 6 months of age and continuously
infused anti-tau antibodies for 3 months via Alzet subcutaneous
osmotic minipump (Figure S4A). We used anti-Ab antibody
HJ3.4 and PBS as negative controls. After 6 weeks, we replaced
each pump with one filled with fresh antibody solution or PBS. At
the time of brain dissection, we verified catheter placement in the
left lateral ventricle of each mouse by cresyl violet staining (Fig-
ure S4B). Only mice with correctly placed catheters were
included in the analyses. To test the stability of the antibodies
after 6 weeks in vivo (Figure S4A), we collected residual pump
contents upon removal from the animals and assessed the anti-
bodies using SDS-PAGE andCoomassie blue staining. Light and
heavy chains were intact, with no fragmentation, and retained
tau binding activity onwestern blot (data not shown). To estimate
the concentration of anti-tau antibodies in CSF and serum during
the infusion, we administered biotinylated HJ8.5 (HJ8.5B) for
48 hr (7.2 mg/day) (Figure S4A). The concentration of freeNeuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc. 405
Figure 3. AFM Analysis of Isolated Tau
Aggregates from P301S Mouse Brain
Tau aggregates were isolated by IP from TBS
lysates of 12-month-old P301S mouse brains
by using anti-tau antibodies (HJ8.5, HJ9.3, and
HJ9.4) and control antibody HJ3.4. Each column
represents the IP material from each antibody.
Black arrows indicate the areas magnified.
Bottom panel shows a magnified area of the
top panel. Scale bar represents 1 mm in all top
panel images and represents 200 nm in bottom
panel images. Morphology of the aggregated
species IPed by each anti-tau antibody appears
unique. Anti-Ab antibody HJ3.4 did not IP any
aggregates.
Neuron
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indicating clearance of the antibody from the CNS to the periph-
ery (Figure S4C). We also detected HJ8.5B bound to human tau
in both CSF and serum, though the concentration was lower than
that of free antibody (Figure S4C).
Anti-Tau Antibody Treatment Reduces Abnormally
Phosphorylated Tau
To determine the extent of tau pathology in P301S mice after
3 months of treatment, we carried out multiple stains for tau
pathology. Brain sections were first assessed by immunostain-
ing with the anti-phospho tau antibody AT8 (Figure 4). AT8 binds
phosphorylated residues Ser202 and Thr205 of both mouse and
human tau (Figure 4) (Goedert et al., 1995). In mice treated
with PBS and HJ3.4, AT8 strongly stained neuronal cell bodies
and the neuropil in multiple brain regions, particularly in the piri-
form cortex, entorhinal cortex, amygdala, and hippocampus
(Figures 4A and 4B). HJ8.5 treatment strongly reduced AT8
staining (Figure 4C), especially in the neuropil. HJ9.3 and
HJ9.4 also decreased AT8 staining but the effects were slightly
less (Figures 4D and 4E). Quantitative analysis of AT8 staining
in piriform cortex (Figure 5A), entorhinal cortex (Figure 5B), and
amygdala (Figure 5C) demonstrated a strong but variable reduc-
tion in phospho-tau in all anti-tau antibody-treated mice. HJ8.5
antibody markedly reduced AT8 staining in piriform cortex, ento-
rhinal cortex, and amygdala. HJ9.3 had slightly decreased
effects compared to HJ8.5, and HJ9.4 had significant effects in
both entorhinal cortex and amygdala but not in the piriform cor-
tex (Figure 5). The hippocampus exhibited much more variable
AT8 staining versus other brain regions, predominantly in cell
bodies, and thus was not statistically different in treatment
versus control groups (Figure 5D). Because it has been reported
that male P301S mice have greater tau pathology than females
(Zhang et al., 2012), we also assessed the effect of both gender
and treatment (Figure S5). In addition to an effect of treatment,
there was significantly more AT8 staining in all brain regions
analyzed in male mice (Figure S5C). However, the effects of
the antibodies were still highly significant and virtually identical
after adjusting for gender (Figure S5D). We also compared the
treatment groups versus controls in males and females sepa-406 Neuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc.rately, and the effects of antibody HJ8.5 remained most signifi-
cant (Figures S5A and S5B).
Correlation of Multiple Staining Modalities
To test for tau amyloid deposition, we used thioflavin S (ThioS) to
stain brain sections (Figure S6). We semiquantitatively assessed
ThioS staining using a blinded rater who gave a score from 1 (no
staining) to 5 (maximum staining) in all control and anti-tau anti-
body-treated mice. By semiquantitative assessment, HJ8.5
treatment significantly reduced ThioS staining compared to
PBS and HJ3.4 (Figures 6A and 6B). We also stained mice
treated with PBS, HJ8.5, and HJ9.3 (n = 6 from each group)
with PHF1 monoclonal antibody, which recognizes tau phos-
pho-residues Ser396 and Ser404 (Otvos et al., 1994). AT8 and
PHF1 staining significantly correlated (r = 0.630, p = 0.005) (Fig-
ure S7A), showing that two anti-phospho tau antibodies to
different tau epitopes give similar results.
Many neurodegenerative diseases, including tauopathies,
exhibit microglial activation in areas of the brain surrounding pro-
tein aggregation and cell injury. We assessed microglial activa-
tion in the treatment groups using anti-CD68 antibody (Macauley
et al., 2011) (Figures S6C–S6G). HJ8.5 and HJ9.3 treatment
reduced microglial activation in piriform cortex, entorhinal cor-
tex, and amygdala compared to controls (Figures S6C–S6G).
HJ9.4 had a weaker effect in the piriform cortex compared to
HJ8.5 and HJ9.3 (Figures S6E–S6G), consistent with the AT8
staining results (Figure 4A). Microglial activation strongly corre-
lated with AT8 staining in all samples (r = 0.511, p = 0.0038)
(Figure S7B).
Anti-Tau Antibodies Reduce Detergent-Insoluble Tau
and Seeding Activity
To determine the level of soluble and insoluble tau in the cortex,
we performed sequential biochemical extraction with RAB
(aqueous buffer), radio immunoprecipitation assay (RIPA) (deter-
gent buffer), and 70% formic acid (FA) to solubilize the final
pellet. We quantified total tau by ELISA with anti-tau antibody
HJ8.7, which detects both human and mouse tau with the
same KD (0.34 pM). We excluded the possibility that the treat-
ment antibodies would interfere with the ELISA by spiking
Figure 4. Anti-Tau Antibodies Strongly Decreased AT8 Staining in P301S Mouse Brain
Representative coronal sections of PBS (A)-, HJ3.4 antibody (B)-, HJ8.5 antibody (C)-, HJ9.3 antibody (D)-, and HJ9.4 antibody (E)-treated 9-month-old P301S
mice stained with biotinylated AT8 antibody in regions including the piriform cortex and amygdala. Scale bar represents 250 mm. Insets in (A)–(E) show the higher
magnification of biotinylated AT8 antibody staining of phosphorylated tau, scale bar represents 50 mm.
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and observing no interference (data not shown). We analyzed
all mice that were assessed by pathological analysis in Figure 5.
Total tau levels in the RAB (Figure 6A)- or RIPA (Figure 6B)-solu-
ble fractions were similar among all groups. We analyzed the
detergent-insoluble/70% FA-soluble fractions by neutralizing
the samples prior to ELISA and western blot. We analyzed every
animal studied and found that HJ8.5 andHJ9.3 decreased deter-
gent-insoluble tau by >50% versus controls (Figure 6C). Repre-
sentative samples (n = 4 from each group) illustrate by western
blot decreased levels of insoluble tau in mice treated with
HJ8.5 and HJ9.3 (Figure S7C). Insoluble tau levels were no
different in HJ9.4-treated groups versus PBS or HJ3.4. We
also assessed human and mouse tau specifically in the deter-
gent-insoluble/70% FA-soluble fractions in n = 6 mice per group
in which the mean AT8 staining reflected the mean values of re-
sults in Figure 4. There was significantly more human tau than
mouse tau in the 70% FA-soluble fraction, and the antibodies
significantly lowered human but not mouse tau in this fraction
(Figures 6D and 6E). In these same samples, we assessed levels
of AT8 immunoreactive signal by ELISA. The AT8 signal was
lower in the antibody-treated samples (Figure 6F), similar to
what was seen for total tau in this fraction.
We hypothesized that a reduction of tau aggregation in brain
would correlate with a reduction in seeding activity. Thus, we
used the cellular biosensor assay to test for P301S brain seeding
activity in the cortical RAB-soluble fractions from the different
treatment groups. Our prior data assessing ISF tau in P301S
mice suggested the possible presence of extracellular tau aggre-
gates in equilibrium with both the biochemically soluble andinsoluble pools of tau (Yamada et al., 2011). We first assessed
intracellular aggregation of RD(DK)-CFP/YFP after treating the
cells with lysates from mice treated with PBS or HJ3.4. Lysates
from these groups strongly induced FRET signal (Figure 7A). We
observed markedly less seeding activity in lysates from the
cortical tissue of mice treated with HJ8.5 and HJ9.3 (Figure 7A).
This was not due to residual antibody in the brain lysates,
because immunoprecipitation of the brain lysates followed by
elution of seeding activity from the antibody/bead complexes
produced the same pattern (Figure 7B). Thus, HJ8.5 and HJ9.3
reduce seeding activity in the P301S tau transgenic mouse brain.
HJ9.4 did not significantly reduce seeding activity (Figure 7A).
Seeding activity strongly correlated with the amount of deter-
gent-insoluble/formic acid-soluble tau detected by ELISA (Pear-
son’s r = 0.529, p = 0.0001) (Figure 7C) but did not correlate with
total tau in RAB fractions (Figure 7D). We hypothesized that
seeding activity is due to tau aggregates present in the RAB-sol-
uble fraction. To test for this, we performed SDD-AGE followed
by western blot. In addition to tau monomer, we observed higher
molecular weight tau species present in 3-month-old P301S
mice and a larger amount present in 9-month-old P301S mice
(Figure 7E). A component of these higher molecular weight
species probably constitutes the seeding activity detected in
the FRET assay and may be in equilibrium with the tau present
in the detergent-insoluble/formic acid-soluble fraction.
Anti-Tau Antibodies Rescue Contextual Fear Deficits
In studies of P301S tau transgenic mice at 9 months of age,
we compared the control and anti-tau antibody-treated groups
in a variety of behaviors. The groups did not differ in locomotorNeuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc. 407
Figure 5. Certain Anti-Tau Antibodies
Strongly Decrease AT8 Staining in P301S
Mouse Brain
Percent of the area covered by biotinylated AT8
staining of abnormally phosphorylated tau in piri-
form cortex (A), entorhinal cortex (B), amygdala
(C), and hippocampus CA1 region (D) in mice
treated with the anti-tau antibodies HJ8.5 (n = 13),
HJ9.3 (n = 15), HJ9.4 (n= 13), the anti-Ab antibody,
HJ3.4 (n = 8), or PBS (n = 16) in 9-month-old
P301S mice. There was reduced AT8 staining in
several different brain regions in the anti-tau anti-
body-treated mice compared to PBS or HJ3.4
antibody-treated mice. HJ8.5 had the largest
effects. **p < 0.01, *p < 0.05, values represent
mean ± SEM.
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ure S8). The ability of the anti-tau antibody treatments to rescue
cognitive deficits in P301S mice was evaluated by assessing the
performance of the mice on the conditioned fear procedure. On
day 1, all four treatment groups of mice exhibited similar levels of
baseline freezing during the first 2 min in the training chamber.
This was confirmed by repeated-measures ANOVA, which failed
to reveal any significant overall main effects or interactions
involving treatment (Figure 8A). In addition, all four groups
showed similar levels of freezing during the tone-shock (T/S)
conditioned stimulus-unconditioned stimulus (CS-US) pairings
(Figure 8A). The general lack of differences in freezing levels
between groups across the three T/S pairings was documented
by a nonsignificant effect of treatment and a nonsignificant geno-
type by minute interaction.
In contrast to the absence of differences among groups during
testing on day 1, there were robust differences in freezing levels
from the contextual fear test (form of associative learning) con-
ducted on day 2 between two of the anti-tau antibody groups
and the PBS+HJ3.4 control mice (Figure 8B). Subsequent
planned comparisons indicated that the HJ8.5 mice showed
significantly elevated freezing levels averaged across the 8 min
test session (Figure 8C) compared to the PBS+HJ3.4 control
group, (F(1,45) = 8.30, p = 0.006), as did to a lesser extent the
HJ9.4 mice, (F(1,45) = 5.60, p = 0.022). Thus, HJ8.5 appeared
to have a stronger effect overall in preserving associative
learning.408 Neuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc.DISCUSSION
One model for the pathogenesis of the
tauopathies holds that aggregates pro-
duced in one cell escape or are released
into the extracellular space to promote
aggregation in neighboring or connected
cells (Clavaguera et al., 2009; deCalignon
et al., 2012; Frost et al., 2009; Kfoury
et al., 2012; Kim et al., 2010; Liu et al.,
2012). We have observed that selection
of therapeutic antibodies that specifically
block tau seeding activity from brain
lysates predicts potent in vivo responsesat least as strong if not stronger than prior reports of active or
passive tau vaccination. We began with a cellular biosensor
assay that is sensitive to the presence of extracellular tau aggre-
gates. We found that brain lysates from P301S transgenic mice
contained seeding activity that could induce further intracellular
aggregation. After screening a panel of anti-tau antibodies, we
selected three with variable activities in blocking tau seeding
activity. We infused these antibodies ICV over 3 months into
P301S tauopathy mice, beginning at a time when pathology
had initiated (6 months). Infusion of the antibodies resulted in
appreciable concentrations of antibody present in both CSF
and serum, consistent with previous reports of efflux of anti-
bodies from the CNS to the periphery (DeMattos et al., 2001;
Strazielle and Ghersi-Egea, 2013). Treatment with HJ8.5, the
most potent antibody in vitro, profoundly reduced tau pathology.
We detected this effect with multiple independent stains,
biochemical analyses of insoluble tau, and by analysis of residual
tau seeding activity present in brain lysates. There was also
improvement in the one behavioral deficit that we detected in
this model. All antibodies block tau aggregate uptake into cells,
and none is observed within cells in the presence or absence of
extracellular aggregates in our assays. The efficacy of these
antibodies implies a clear role for extracellular tau in the patho-
genesis of neuropathology that was previously thought to be
cell autonomous. This work extends our prior findings, which
suggest that aggregate flux may occur in the setting of intracel-
lular pathology, raising the possibility of therapies that can assist
Figure 6. Insoluble Tau Levels Are Reduced by Antibodies HJ8.5 and HJ9.3 in P301S Mice
(A–C) Thecortex of all the treatedmice (PBS [n=16],HJ3.4 antibody [n =8], HJ8.5 [n=13],HJ9.3 [n=15], andHJ9.4 [n=13])were sequentially extractedbyRAB (A),
RIPA (B), and 70%FA (C) and their tau levelswere quantified byELISA. Therewere no statistical differences in soluble tau levels inRABandRIPA fractions between
the groups. However, therewas a significant decrease of insoluble tau levels in 70%FA fractions in the HJ8.5 andHJ9.3 anti-tau antibody-treatedmice compared
to the PBS or HJ3.4 antibody-treated groups. Insoluble tau levels in the HJ9.4 antibody-treated mice were not different from the control groups. **p < 0.01.
(D–F) Levels of human tau (D), mouse tau (E), and phospho tau at Ser202 and Thr205 (F) levels were assessed in 70% FA fractions by specific anti-human, anti-
mouse, or anti-phospho tau antibodies by ELISA (n = 6 mice per treatment group). There was a decrease in human tau levels in all groups of anti-tau antibody-
treated mice and no change in mouse tau levels. In 70% FA fractions, we also found that phospho tau at Ser202 and Thr205 as detected by AT8 reactivity was
reduced in anti-tau antibody-treated mice compared to controls, similar to total human tau. Values represent mean ± SEM.
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work has important implications for the design of therapeutic an-
tibodies and suggests that targeting seeding activity in particular
may produce the most effective agents.
Mechanism-Based Antibody Therapy
Several prior active and passive peripheral immunotherapy ap-
proaches against tau have also reduced tau pathology and
improved behavioral deficits, but the underlying rationale for
antibody choice was based either on a phospho-epitope, reac-
tivity with neurofibrillary tangles, or was not stated (Asuni et al.,
2007; Bi et al., 2011; Boimel et al., 2010; Boutajangout et al.,
2010, 2011; Chai et al., 2011; Troquier et al., 2012). One tau im-
munization study, performed by vaccinatingmice with full-length
tau, induced pathology in wild-type mice (Rosenmann et al.,
2006). However, subsequent active immunization approaches
with phospho-tau peptides in tau transgenic models reduced
tau pathology (Bi et al., 2011; Boimel et al., 2010) and showed
behavioral improvement (Asuni et al., 2007; Boutajangout
et al., 2010; Troquier et al., 2012). In a passive immunization
study, JNPL3 tau transgenic mice were administered the PHF1
antibody intraperitoneally at 2–3months of age, prior to the onset
of tauopathy. PHF-1 targets a pathological form of abnormally
phosphorylated tau (Otvos et al., 1994). Treatment reduced tau
pathology and improved behavior (Boutajangout et al., 2011).
However, while it decreased insoluble phosphorylated tau, total
insoluble tau did not change. In another passive immunization
study, JNPL3 and P301S mice (at age 2–3 months, prior to theonset of tauopathy) were peripherally administered the PHF1
or MC1 antibody, which targets an aggregate-associated
epitope (Jicha et al., 1999). Both treatments improved tau
pathology and delayed the onset of motor dysfunction (Chai
et al., 2011). In these prior studies, the mechanism of action of
the antibodies was not clear, and none was explicitly tested.
Indeed, some proposed an intracellular mechanism (Sigurdsson,
2009). Moreover, no study appears to have produced the magni-
tude of reduction in tau pathology that we observed here, with
the caveats that we infused antibodies into the CNS, while the
other studies utilized peripheral infusion and different animal
models were utilized.
We designed this study explicitly to test a prediction that
extracellular tau seeds are a key component of pathogenesis.
We began with a selection process to pick antibodies capable
of blocking tau seeding in vitro, purposely testing agents with a
range of predicted activities. All antibodies that we tested in vivo
effectively block aggregate uptake and seeding, providing a
basis for their observed activity. We have only tested three ther-
apeutic antibodies in vivo. Thus, the correlations with the in vitro
assays could be through chance. Further studies of anti-tau
antibodies with variable potencies in the seeding assay will
help address this question. In addition, correlation of antibody
affinity, epitope, isotype, glycosylation, and ability to bind phos-
phorylated forms of tau will be important to assess in future
studies. This study also reports the effects of direct, intra-CNS
infusion of anti-tau antibodies. Despite the fact that the anti-
bodies utilized each target different tau epitopes and do notNeuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc. 409
Figure 7. Anti-Tau Antibody-Treated P301S
Mice Have Decreased Tau Seeding Activity
in Cortical Extracts as Detected by FRET
Assay
(A) Tau seeding activity was measured with RAB-
soluble fractions of all PBS (n = 16)-, HJ3.4 (n = 8)-,
HJ8.5 (n = 13)-, HJ9.3 (n = 15)-, and HJ9.4 (n = 13)-
treated mice on HEK293 cells by FRET assay.
HEK293 cells were cotransfected with RD (DK280)-
CFP and RD (DK280)-YFP. Eighteen hours later,
RAB-soluble fractions were added to cells. Seeding
activity was significantly reduced in HJ8.5, and
HJ9.3 antibody-treated mice compared to the PBS-
or HJ3.4 antibody-treated mice. RAB-soluble frac-
tions fromHJ9.4 antibody-treatedmice did not have
decreased seeding activity compared to the PBS or
HJ3.4 antibody RAB-soluble fractions. ***p < 0.001,
values represent mean ± SEM.
(B) RAB-soluble fractions from tau KO, PBS-
treated, and the anti-tau antibody-treated mice
were incubated with unconjugated protein-G-
agarose beads at 4C with end-over-end rotation
for 24 hr. This precipitates any residual antibody in
the brain, including antibody bound to tau seeds.
Elution of any seeding activity from the antibody/
bead complexes was measured by FRET assay.
There was significantly less seeding activity
observed in HJ8.5 and HJ9.3 antibody-treated mice
versus PBS-treated mice ****p < 0.0001, values
represent mean ± SEM.
(C) Seventy percent FA fractions of 9-month-old
P301S brain cortex region of all treated groups
analyzed by ELISA showed a strong correlation with
FRET analysis performed with the RAB-soluble
fractions.
(D) Comparison between tau levels (x axis) and
seeding activity (y axis) present in RAB-soluble
fractions of 9-month-old P301S brain cortex of all
treated mice assessed. There was no significant
correlation between these two measures.
(E) Tau species in the RAB-soluble fractions of 3-month-old knockout (KO), 3-month-old wild-type (WT), 3-month-old P301S, and 9-month-old PBS-treated
P301S mice were separated on SDD-AGE, followed by western blotting. Polyclonal mouse anti-tau antibody was used for detecting tau species. High molecular
weight tau species present in the RAB-soluble fraction in both 3-month-old P301S mice and larger amounts present in 9-month-old P301S mice.
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load both immunohistologically and biochemically, and two
significantly improved memory, one to a greater extent than
the other. Effects on tau pathology also correlated very well
with a reduction in intrinsic seeding activity.
HJ8.5 and HJ9.3 strongly decreased pathological tau seeds
in vivo. A strong reduction in tau pathology might occur by pre-
venting induction of tau aggregation in neighboring cells. While
HJ9.4 did not decrease pathology as potently, it did decrease
tau pathology in the amygdala. The variation in effectiveness in
different brain regions among the antibodies may be due to the
formation of region-specific aggregate conformers for which
the antibodies have subtle differences in binding affinity.
Once extracellular tau aggregates are sequestered by anti-tau
antibodies in vivo, their metabolic fate is not yet clear. After
3 months of antibody administration, we found reduced micro-
glial activation, presumably due to less tau-related pathology
and neurodegeneration. Several months of passive immuniza-
tion with anti-Ab antibodies has also been noted to reduce410 Neuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc.microgliosis (Wilcock et al., 2003). Themechanismbywhich anti-
body/tau complexes are cleared in vivo, and the mechanism via
which they decrease tau pathology, remains to be definitively
clarified. It has been suggested that immunization with anti-
a-synuclein antibodies clears a-synuclein aggregates by pro-
moting lysosomal degradation (Masliah et al., 2011). A recent
study with anti-a-synuclein antibodies showed that the anti-
bodies targeted a-synuclein clearance mainly via microglia, pre-
sumably through Fc receptors (Bae et al., 2012). Neurons
express Fcg receptors (Andoh and Kuraishi, 2004; Mohamed
et al., 2002) and may be able to internalize IgG complexed with
antigen by high-affinity FcgRI receptor (Ravetch and Bolland,
2001). Internalized tau antibodies may contact tau in endosomes
and eventually induce clearance of intracellular tau aggregates
by the endosomal/lysosomal system (Sigurdsson, 2009).
Though the anti-tau antibodies used in our current study can
bind extracellular tau assemblies, we found no evidence of sig-
nificant localization within cells. However, that does not rule
out the possibility that cells in vivo take up antibody/tau
Figure 8. Contextual Fear Conditioning Deficits in P301S Tau Transgenic Mice Are Rescued by HJ8.5 and HJ9.4 Antibody Treatments
(A) On day 1 of conditioned fear testing, no differences were observed among groups in freezing levels during either the 2min baseline condition or the tone/shock
(T/S) training as indicated by the lack of a significant main or interaction effects involving treatment after repeated-measures ANOVAs on these data.
(B) In contrast, a significant effect of treatment (*p = 0.019) and a significant treatment by minutes interaction (**p = 0.0001) were observed after a repeated-
measures ANOVA on freezing levels during the contextual fear testing on day 2. Only the HJ9.4 group showed significant habituation fromminute 1 versusminute
8 (#p = 0.002).
(C) Subsequent planned comparisons showed that freezing in the HJ8.5 and HJ9.4 tau antibody groups was significantly increased relative to the PBS+HJ3.4
control group when averaged across the 8 min session (**p = 0.006 and *p = 0.022, respectively). However, further analyses of the data showed that the largest
differences between the HJ9.4 group and the PBS+HJ3.4 controls occurred during minute 2 (yp = 0.004), while the largest differences between the HJ8.5-treated
mice and the control group were found during minutes 4–7 (yyp < 0.004) as depicted in (B). Values represent mean ± SEM.
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has recently been shown that antibodies complexed with viruses
can bind to the cytosolic IgG receptor TRIM21, targeting the anti-
body/virus complex to the proteasome (Mallery et al., 2010). In
addition, antibodies bound to TRIM21 were shown to activate
immune signaling (McEwan et al., 2013). Interestingly, there is
also evidence in the P301S model of tauopathy that the innate
immune system is activated prior to the development of signifi-
cant tau pathology and that early immunosuppression attenu-
ates tau pathology (Yoshiyama et al., 2007). It is possible that
antibodies capture tau aggregates induced by inflammation,
reducing subsequent aggregate-induced inflammation and dis-
ease progression.
Extracellular Tau and Spreading of Tau Pathology
Our work implicitly tests the role of extracellular tau in pathogen-
esis. It is now clear that extracellular tau aggregates can trigger
fibril formation of native tau inside cells, whether their source is
recombinant protein or tau extracted from mammalian cells
(Clavaguera et al., 2009; de Calignon et al., 2010; Frost et al.,
2009; Guo and Lee, 2011; Liu et al., 2012). We originally hypoth-
esized a role for free tau aggregates (i.e., not membrane
enclosed) as mediators of trans-cellular propagation based on
our prior work, because HJ9.3 added to the cell media blocked
internalization and immunoprecipitated free fibrils (Kfoury et al.,
2012).
In animal models, tau aggregates can apparently spread from
one region to another (de Calignon et al., 2012; Liu et al., 2012).
We found that monomeric tau is constantly released in vivo into
the brain interstitial fluid even under nonpathological conditions
(Yamada et al., 2011). We also found that exogenous aggregates
would reduce levels of soluble ISF tau, suggesting that seeding
and/or sequestration phenomena can occur in this space
(Yamada et al., 2011). Taken together, evidence supports the
concept that extracellular tau aggregates form and can be takenup by adjacent cells, connected cells, or possibly back into the
same cell, thereby increasing the burden of protein aggregation.
This evidence makes a clear prediction: therapy that captures
extracellular seeding activity should ameliorate disease.
The Role of Tau Flux in Pathogenesis
It would not be predicted a priori that a mouse model such as
P301S, which drives mutant tau expression via the prion pro-
moter in virtually all neurons, should benefit from antibody treat-
ments that block trans-cellular propagation of aggregation. In
theory, pathology could occur independently in all neurons that
express this aggregation-prone protein. However, our prior
work in tissue culture suggested a role for flux of tau aggregates
(Kfoury et al., 2012). While the model of aggregate flux requires
further testing, our results here are consistent with this idea,
since antibody treatment profoundly reduced intracellular tau
pathology. We predict that antibodies that block tau uptake
will create a ‘‘sink’’ in the extracellular space that will promote
clearance by another mechanism, possibly involving microglia.
Therapeutic Antibodies and Targeting Seeding Activity
There are increasing efforts to develop therapeutic antibodies
that target aggregation-prone proteins that accumulate within
cells. The principal criteria have been that the antibodies will
bind epitopes known to accumulate in diseased brain. This
approach may or may not lead to antibodies with optimal activity
in vivo. Our work supports a model of therapeutic antibody
development that emphasizes efficacy in blocking the seeding
activity present in the brain, rather than specific linear epitopes.
Using this approach we identified antibodies with higher
apparent efficacy than has previously been reported. In an
extension of the prion hypothesis, we propose further that
distinct tau aggregate ‘‘strains’’ may predominate in patients
with different types of tauopathy, and these may have unique
sensitivities to different antibodies. The use of sensitive in vitroNeuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc. 411
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development and optimization of antibody-based therapies.
The strong protective effect of the anti-tau antibodies, partic-
ularly with the HJ8.5 antibody, suggests that this type of
approach should be considered as a treatment strategy for
human tauopathies. In addition to our ICV approach, it will be
important to determine the PK/PD response with peripheral
administration of these antibodies. The tau seeding assay may
be useful to monitor target engagement by the antibodies.
EXPERIMENTAL PROCEDURES
Antibodies
HJ9.3 and HJ9.4mousemonoclonal antibodies were raised by immunizing tau
knockout mice (The Jackson Laboratory) against mouse tau, and HJ8.5 and
HJ8.7 monoclonal antibodies were raised by immunizing tau knockout mice
against human tau. Detailed information of the different antibodies used is pro-
vided in Supplemental Information.
Animals
P301S tau transgenic mice (purchased from The Jackson Laboratory), which
express the P301S human T34 isoform (1N4R), were generated and character-
ized previously (Yoshiyama et al., 2007). These mice are on a B6C3 back-
ground. Animal procedures were performed according to protocols approved
by theAnimal StudiesCommittee atWashingtonUniversitySchool ofMedicine.
Surface Plasmon Resonance
Surface plasmon resonance experiments were performed as described with
minor modifications (Basak et al., 2012) (see Supplemental Information).
Intracerebroventricular Injection Procedure
Intracerebroventricular (ICV) infusions were performed by Alzet osmotic
pumps, 2006 model (Durect). Detailed surgery procedure is provided in
Supplemental Information.
Immunofluorescence
Immunofluorescence was performed as previously described (Kfoury et al.,
2012) with some modifications (see Supplemental Information).
Cell Culture/Seeding Assay: P301S Brain Lysates and Antibody
Treatment
Experiments were performed similar to those previously described (Kfoury
et al., 2012) with some modifications (see Supplemental Information).
Immunoprecipitation
Immunoprecipitation was performed similar to previously described (Kfoury
et al., 2012) with some modifications (see Supplemental Information).
Depletion and Immunoprecipitation of Tau Aggregates from P301S
Brain Using Tau-Specific Antibodies
Immunoprecipitation of tau and tau aggregates was performed as described
(Kfoury et al., 2012) with some modifications (see Supplemental Information).
Atomic Force Microscope
Atomic force microscopy was performed as previously described (Kfoury
et al., 2012) with some modifications (see Supplemental Information).
Histology
After 12weeks of the treatment, P301Smicewere anesthetizedwith intraperito-
neal pentobarbital (200mg/kg) followed by perfusionwith 3 U/ml heparin in cold
Dulbecco’s PBS. Detailed procedure is provided in Supplemental Information.
Immunohistochemistry
Immunohistochemistry was performed as described previously (DeMattos
et al., 2001) with minor modifications (see Supplemental Information).412 Neuron 80, 402–414, October 16, 2013 ª2013 Elsevier Inc.Brain Tissue Extraction
Brain tissue extractions were performed as described previously (Yamada
et al., 2011) with minor modifications (see Supplemental Information).
Interperitoneal Injection and ICV Administration of Biotinylated
HJ8.5 Antibody
Mouse monoclonal HJ8.5 antibody was biotinylated according to the manu-
facturer’s instructions (Sulfo-NHS-LC-Biotin kit, Pierce). Detailed procedure
is provided in Supplemental Information.
ELISA to Detect Free HJ8.5B and HJ8.5B Bound to Tau
The concentration of free HJ8.5B was determined in serum and CSF of mice
48 hr after IP or ICV administration. Detailed procedure is provided in Supple-
mental Information.
Semidenaturing Detergent-Agarose Gel Electrophoresis
SDD-AGE was performed as described previously (Kryndushkin et al., 2003)
with minor modifications (see Supplemental Information).
Electrophoresis and Immunoblotting
These experiments were performed as described previously (Yamada et al.,
2011) with minor modifications (see Supplemental Information).
Tau Sandwich ELISA Assays
ELISAs were performed as described previously (Yamada et al., 2011) with
minor modifications (see Supplemental Experimental Procedures).
Statistical Analysis Applying Treatment and Gender as Factors
The control group (PBS and HJ3.4) mean was compared with each treat-
ment group mean. Detailed procedures are provided in Supplemental
Information.
Behavioral Tests
Tests were performed as described previously (Ghoshal et al., 2012; Sato
et al., 2012; Wozniak et al., 2007) with minor modifications (see Supplemental
Information).
Statistical Analyses of Behavioral Data
ANOVA models were typically used to analyze the behavioral data (Systat 12,
Systat Software). Detailed procedures are provided in Supplemental
Information.
Statistical Analysis of Pathological and Biochemical Data
All data are presented asmean±SEM, anddifferent conditionswere compared
using one-way ANOVA followed by Dunnett’s post hoc test to compare
controls with treatment groups. Statistical significance was set at p < 0.05.
Statistics were performed using GraphPad Prism 5.04 forWindows (GraphPad
Software). For quantitative assessment of AT8 staining, gender is a significant
factor, so results were adjusted by gender using SAS version 9.2 software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and eight figures and can be found with this article online at http://dx.doi.
org/10.1016/j.neuron.2013.07.046.
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